2-(3-chlorophenyl)-2,7-diazaspiro[4.4]nonane | 1181220-89-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(3-chlorophenyl)-2,7-diazaspiro[4.4]nonane
• CAS: 1181220-89-2
• 化学式: C₁₃H₁₇ClN₂
• 分子量: 236.744
• InChiKey: LVZIPZGNYQAESW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-chlorophenyl)-2,7-diazaspiro[4.4]nonane 、 6-azido-2-{[3-(3-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]thio}hexanoic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(5-azido-1-{[7-(3-chlorophenyl)-2,7-diazaspiro[4.4]non-2-yl]carbonyl}pentyl)thio]-3-(3-chlorophenyl)quinazolin-4(3H)-one
  参考文献：
  名称：

  [EN] INHIBITORS OF CHECKPOINT KINASES
  [FR] INHIBITEURS DE CHECKPOINT KINASES

  摘要：

  这项即时发明提供了包含替代硫喹唑酮的化合物，这些化合物抑制CHK1活性。该发明还提供了包含这种抑制性化合物的组合物，以及通过向需要癌症治疗的患者施用该化合物来抑制CHK1活性的方法。

  公开号：

  WO2009102537A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018141984A1

  公开（公告）日：2018-08-09

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors of Formulas (I) and (II). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及具有式(I)和(II)的O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的过程，以及利用这些化合物和组合物预防和治疗OGA抑制对其有益的疾病的用途，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。
• SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE
  申请人：Ando Makoto

  公开号：US20110071129A1

  公开（公告）日：2011-03-24

  [Problem] To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders. [Means for Resolution] Provided are compound of a formula (I): [wherein R 1 a and R 1 b each are a hydrogen atom, etc.; R 2 is a hydrogen atom, a C 1-6 alkyl, etc.; Ar 1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar 2 is a group to be formed by removing two hydrogen atoms from a 6-membered aromatic carbon ring, a 6-membered aromatic nitrogen-containing hetero ring, etc.; Ar 3 is a mono- or bi-cyclic aromatic carbon ring or aromatic hetero ring; m 1 , m 2 , m 3 and m 4 each are independently 0, 1, 2, 3 or 4, provided that the total of m 1 and m 2 is from 2 to 6, the total of m 3 and m 4 is from 2 to 6]. The compounds are useful as medicines for central system disorders, cardiovascular disorders, metabolic disorders.

  [问题] 提供一种黑色素浓集激素受体拮抗剂，可用作中枢系统疾病、心血管疾病和代谢性疾病的药物。[解决方案] 提供了一种公式（I）的化合物：[其中R1a和R1b分别是氢原子等；R2是氢原子、C1-6烷基等；Ar1是6元芳香碳环基或6元芳香氮杂环基；Ar2是从6元芳香碳环、6元芳香氮杂环等中去除两个氢原子形成的基团；Ar3是单环或双环芳香碳环或芳香杂环；m1、m2、m3和m4各自独立地为0、1、2、3或4，前提是m1和m2的总和为2到6，m3和m4的总和为2到6]。这些化合物可用作中枢系统疾病、心血管疾病和代谢性疾病的药物。
• EP2301936A1
  申请人：——

  公开号：EP2301936A1

  公开（公告）日：2011-03-30
• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20200048267A1

  公开（公告）日：2020-02-13

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.